MORRIS PLAINS, N.J., Feb. 2, 2010 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the second quarter ended December 31, 2009. The Company also highlighted recent key developments and planned activities for its clinical pipeline.
